Failure to Follow-Up After Colorectal Cancer Screening Translates into Preventable Deaths: Rachel Issaka, MD, MAS
ACP 2025: Issaka, from the Fred Hutchinson Cancer Center, told internists that three-quarters of CRC deaths can be attributed to 3 types of screening failure.
Rachel Issaka, MD, MAS, associate professor of medicine and the Kathryn Surace-Smith endowed chair in health equity research at Fred Hutchinson Cancer Center shared a striking statistic in her presentation on colorectal cancer screening at the 2025 ACP Internal Medicine Meeting in New Orleans: approximately 76% of cancer deaths are attributable to a failure in screening, whether a complete failure to screen, failure to screen at the appropriate interval, or failure to follow-up properly after screening.
Patient Care© spoke to Issaka after her presentation and asked which of 3 primary failures she feels is the most dangerous. She discusses that and also talks about the benefits and limitations of blood-based CRC detection tests now in development.
Lebrikizumab Demonstrates Efficacy, Safety in Patients With Skin of Color With AD
June 11th 2025RAD 2025. Lebrikizumab improved skin clearance, itch, and pigmentation in patients with skin of color and atopic dermatitis, with strong safety data through 24 weeks, according to late-breaking data.
